

MEDICINOVA INC  
Form 425  
December 15, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): December 15, 2009**

**MEDICINOVA, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

**DELAWARE**  
**(State or Other Jurisdiction**

**001-33185**  
**(Commission File Number)**

**33-0927979**  
**(IRS Employer**

**of Incorporation)**

**4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO, CA 92122**

**Identification No.)**

Edgar Filing: MEDICINOVA INC - Form 425

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On December 15, 2009, MediciNova, Inc. ( MediciNova ) and Avigen, Inc. ( Avigen ) issued a press release (the Press Release ) confirming the previously announced deadline for Avigen stockholders to elect the merger consideration they will receive upon closing of the proposed merger of the companies. A copy of the Press Release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits.*

99.1 Press Release dated December 15, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, MediciNova has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDICINOVA, INC.**

Date: December 15, 2009

By: /s/ SHINTARO ASAKO  
Name: **Shintaro Asako**  
Title: **Chief Financial Officer**